Table 6.

Prognostic factors for survival in different studies

Study	Year	n	Treatment	Prognostic factors
Mondazzi et al.8	1994	84	TACE	Age, total bilirubin, Child–Pugh score, tumour size, change in AFP
Livraghi et al.16	1995	746	PEI	Child–Pugh score, tumour stage
Allgaier et al.17	1998	132	TACE/PEI	Child–Pugh score, Okuda stage, PVT, AFP
Llado et al.9	2000	143	TACE	Ascites, AFP, tumour size, Child–Pugh score, pattern of Lipiodol intake, PVT
El Khaddari et al.18	2002	72	TACE	Child–Pugh score, interval between treatment
Grieco et al.19	2003	81	TACE	PVT, bilirubin, AFP, tumour size, Okuda, CLIP, BCLC
Goin et al.20	2005	121	Y-90 (Theraspheres)	Infiltrative tumour, AST/ALT > 5 ULN, tumour burden > 50%, albumin < 3.0 g/dl, bilirubin > 2 mg/dl
Sato et al.21	2008	229	Y-90 (Theraspheres)	Cirrhosis, infiltrative HCC, PVT, AFP, tumour burden

TACE, transarterial chemoembolization; PEI, percutaneous ethanol injection; AFP, alphafetoprotein; PVT, portal vein thrombosis; CLIP, Cancer of the Liver Italian Programme; BCLC, Barcelona Clinic Liver Cancer; Y-90, yttrium 90 radioembolization; HCC, hepatocellular carcinoma